Could a common Virus-Fighting drug extend lives of brain cancer patients?
NCT ID NCT04116411
First seen Jan 05, 2026 · Last updated Jun 18, 2026 · Updated 30 times
Summary
This study tests whether adding the anti-viral drug valganciclovir to standard treatment can help people with glioblastoma, an aggressive brain cancer, live longer. The drug targets cytomegalovirus (CMV), which is often found in these tumors and may make them more aggressive. About 220 newly diagnosed patients will receive either valganciclovir or a placebo alongside chemotherapy and radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Oslo University Hospital
Oslo, Norway
-
SE01 Karolinska University Hospital
Solna, Stockholm County, SE17164, Sweden
-
Stavanger University Hospital
Stavanger, Norway
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.